index	sentence	Gene	Disease
0	Association Study of SLCO1B3 and ABCC3 Genetic Variants in Gallstone Disease	SLCO1B3	Gallstone Disease
1	Association Study of SLCO1B3 and ABCC3 Genetic Variants in Gallstone Disease	SLCO1B3	Gallstone Disease
2	Association Study of SLCO1B3 and ABCC3 Genetic Variants in Gallstone Disease	ABCC3	Gallstone Disease
3	Association Study of SLCO1B3 and ABCC3 Genetic Variants in Gallstone Disease	ABCC3	Gallstone Disease
4	The aim of this study was to investigate the association between SLCO1B3 (rs4149117:G>T, rs7311358:A>G) and ABCC3 (rs4793665:T>C, rs11568591:G>A) genetic variants and susceptibility to cholesterol gallstone disease, as well as gallstone composition	SLCO1B3	cholesterol gallstone disease
5	The aim of this study was to investigate the association between SLCO1B3 (rs4149117:G>T, rs7311358:A>G) and ABCC3 (rs4793665:T>C, rs11568591:G>A) genetic variants and susceptibility to cholesterol gallstone disease, as well as gallstone composition	SLCO1B3	gallstone
6	The aim of this study was to investigate the association between SLCO1B3 (rs4149117:G>T, rs7311358:A>G) and ABCC3 (rs4793665:T>C, rs11568591:G>A) genetic variants and susceptibility to cholesterol gallstone disease, as well as gallstone composition	SLCO1B3	cholesterol gallstone disease
7	The aim of this study was to investigate the association between SLCO1B3 (rs4149117:G>T, rs7311358:A>G) and ABCC3 (rs4793665:T>C, rs11568591:G>A) genetic variants and susceptibility to cholesterol gallstone disease, as well as gallstone composition	SLCO1B3	gallstone
8	The aim of this study was to investigate the association between SLCO1B3 (rs4149117:G>T, rs7311358:A>G) and ABCC3 (rs4793665:T>C, rs11568591:G>A) genetic variants and susceptibility to cholesterol gallstone disease, as well as gallstone composition	ABCC3	cholesterol gallstone disease
9	The aim of this study was to investigate the association between SLCO1B3 (rs4149117:G>T, rs7311358:A>G) and ABCC3 (rs4793665:T>C, rs11568591:G>A) genetic variants and susceptibility to cholesterol gallstone disease, as well as gallstone composition	ABCC3	gallstone
10	The aim of this study was to investigate the association between SLCO1B3 (rs4149117:G>T, rs7311358:A>G) and ABCC3 (rs4793665:T>C, rs11568591:G>A) genetic variants and susceptibility to cholesterol gallstone disease, as well as gallstone composition	ABCC3	cholesterol gallstone disease
11	The aim of this study was to investigate the association between SLCO1B3 (rs4149117:G>T, rs7311358:A>G) and ABCC3 (rs4793665:T>C, rs11568591:G>A) genetic variants and susceptibility to cholesterol gallstone disease, as well as gallstone composition	ABCC3	gallstone
12	The results of this study suggest that polymorphisms of SLCO1B3 and ABCC3 genes are not a valuable marker of gallstone disease susceptibility and do not influence gallstone composition.	SLCO1B3	gallstone disease
13	The results of this study suggest that polymorphisms of SLCO1B3 and ABCC3 genes are not a valuable marker of gallstone disease susceptibility and do not influence gallstone composition.	SLCO1B3	gallstone
14	The results of this study suggest that polymorphisms of SLCO1B3 and ABCC3 genes are not a valuable marker of gallstone disease susceptibility and do not influence gallstone composition.	SLCO1B3	gallstone disease
15	The results of this study suggest that polymorphisms of SLCO1B3 and ABCC3 genes are not a valuable marker of gallstone disease susceptibility and do not influence gallstone composition.	SLCO1B3	gallstone
16	The results of this study suggest that polymorphisms of SLCO1B3 and ABCC3 genes are not a valuable marker of gallstone disease susceptibility and do not influence gallstone composition.	ABCC3	gallstone disease
17	The results of this study suggest that polymorphisms of SLCO1B3 and ABCC3 genes are not a valuable marker of gallstone disease susceptibility and do not influence gallstone composition.	ABCC3	gallstone
18	The results of this study suggest that polymorphisms of SLCO1B3 and ABCC3 genes are not a valuable marker of gallstone disease susceptibility and do not influence gallstone composition.	ABCC3	gallstone disease
19	The results of this study suggest that polymorphisms of SLCO1B3 and ABCC3 genes are not a valuable marker of gallstone disease susceptibility and do not influence gallstone composition.	ABCC3	gallstone
20	Monogenic predisposition has been described in carriers of rare mutations in phosphatidylcholine transporter (ABCB4) and cholesterol transporter (ABCB11) genes, and more recently, a common gene polymorphism in ABCG8 was associated with cholesterol gallstone disease.	ABCB4	cholesterol gallstone disease
21	Monogenic predisposition has been described in carriers of rare mutations in phosphatidylcholine transporter (ABCB4) and cholesterol transporter (ABCB11) genes, and more recently, a common gene polymorphism in ABCG8 was associated with cholesterol gallstone disease.	ABCB4	cholesterol gallstone disease
22	Monogenic predisposition has been described in carriers of rare mutations in phosphatidylcholine transporter (ABCB4) and cholesterol transporter (ABCB11) genes, and more recently, a common gene polymorphism in ABCG8 was associated with cholesterol gallstone disease.	ABCB11	cholesterol gallstone disease
23	Monogenic predisposition has been described in carriers of rare mutations in phosphatidylcholine transporter (ABCB4) and cholesterol transporter (ABCB11) genes, and more recently, a common gene polymorphism in ABCG8 was associated with cholesterol gallstone disease.	ABCB11	cholesterol gallstone disease
24	Monogenic predisposition has been described in carriers of rare mutations in phosphatidylcholine transporter (ABCB4) and cholesterol transporter (ABCB11) genes, and more recently, a common gene polymorphism in ABCG8 was associated with cholesterol gallstone disease.	ABCG8	cholesterol gallstone disease
25	Monogenic predisposition has been described in carriers of rare mutations in phosphatidylcholine transporter (ABCB4) and cholesterol transporter (ABCB11) genes, and more recently, a common gene polymorphism in ABCG8 was associated with cholesterol gallstone disease.	ABCG8	cholesterol gallstone disease
26	The aim of this study was to investigate the association between SLCO1B3 (rs4149117:G>T, rs7311358:A>G) and ABCC3 (rs4793665:T>C, rs11568591:G>A) genetic variants and susceptibility to cholesterol gallstone disease, as well as gallstone composition.	SLCO1B3	cholesterol gallstone disease
27	The aim of this study was to investigate the association between SLCO1B3 (rs4149117:G>T, rs7311358:A>G) and ABCC3 (rs4793665:T>C, rs11568591:G>A) genetic variants and susceptibility to cholesterol gallstone disease, as well as gallstone composition.	SLCO1B3	gallstone
28	The aim of this study was to investigate the association between SLCO1B3 (rs4149117:G>T, rs7311358:A>G) and ABCC3 (rs4793665:T>C, rs11568591:G>A) genetic variants and susceptibility to cholesterol gallstone disease, as well as gallstone composition.	SLCO1B3	cholesterol gallstone disease
29	The aim of this study was to investigate the association between SLCO1B3 (rs4149117:G>T, rs7311358:A>G) and ABCC3 (rs4793665:T>C, rs11568591:G>A) genetic variants and susceptibility to cholesterol gallstone disease, as well as gallstone composition.	SLCO1B3	gallstone
30	The aim of this study was to investigate the association between SLCO1B3 (rs4149117:G>T, rs7311358:A>G) and ABCC3 (rs4793665:T>C, rs11568591:G>A) genetic variants and susceptibility to cholesterol gallstone disease, as well as gallstone composition.	ABCC3	cholesterol gallstone disease
31	The aim of this study was to investigate the association between SLCO1B3 (rs4149117:G>T, rs7311358:A>G) and ABCC3 (rs4793665:T>C, rs11568591:G>A) genetic variants and susceptibility to cholesterol gallstone disease, as well as gallstone composition.	ABCC3	gallstone
32	The aim of this study was to investigate the association between SLCO1B3 (rs4149117:G>T, rs7311358:A>G) and ABCC3 (rs4793665:T>C, rs11568591:G>A) genetic variants and susceptibility to cholesterol gallstone disease, as well as gallstone composition.	ABCC3	cholesterol gallstone disease
33	The aim of this study was to investigate the association between SLCO1B3 (rs4149117:G>T, rs7311358:A>G) and ABCC3 (rs4793665:T>C, rs11568591:G>A) genetic variants and susceptibility to cholesterol gallstone disease, as well as gallstone composition.	ABCC3	gallstone
34	The components of gallstones were compared between the ABCC3 and SLCO1B3 genotypes	ABCC3	gallstones
35	The components of gallstones were compared between the ABCC3 and SLCO1B3 genotypes	ABCC3	gallstones
36	The components of gallstones were compared between the ABCC3 and SLCO1B3 genotypes	SLCO1B3	gallstones
37	The components of gallstones were compared between the ABCC3 and SLCO1B3 genotypes	SLCO1B3	gallstones
38	There were no statistically significant differences in the analyzed gallstone components of total cholesterol, bilirubin, CaCO3, or total bile acids between patients with different ABCC3 and SLCO1B3 genotypes (Table 3, Table 4 and Table 5)	ABCC3	gallstone
39	There were no statistically significant differences in the analyzed gallstone components of total cholesterol, bilirubin, CaCO3, or total bile acids between patients with different ABCC3 and SLCO1B3 genotypes (Table 3, Table 4 and Table 5)	ABCC3	gallstone
40	There were no statistically significant differences in the analyzed gallstone components of total cholesterol, bilirubin, CaCO3, or total bile acids between patients with different ABCC3 and SLCO1B3 genotypes (Table 3, Table 4 and Table 5)	SLCO1B3	gallstone
41	There were no statistically significant differences in the analyzed gallstone components of total cholesterol, bilirubin, CaCO3, or total bile acids between patients with different ABCC3 and SLCO1B3 genotypes (Table 3, Table 4 and Table 5)	SLCO1B3	gallstone
42	However, substantial variability in gallstone composition between individuals observed in the current study was not related to SLCO1B3 nor ABCC3 genotypes	SLCO1B3	gallstone
43	However, substantial variability in gallstone composition between individuals observed in the current study was not related to SLCO1B3 nor ABCC3 genotypes	SLCO1B3	gallstone
44	However, substantial variability in gallstone composition between individuals observed in the current study was not related to SLCO1B3 nor ABCC3 genotypes	ABCC3	gallstone
45	However, substantial variability in gallstone composition between individuals observed in the current study was not related to SLCO1B3 nor ABCC3 genotypes	ABCC3	gallstone
46	Negative results suggest that common polymorphisms in SLCO1B3 and ABCC3 genes do not influence the function of the encoded transporters to a large extent, and are not clinically important in the case of gallstone disease	SLCO1B3	gallstone disease
47	Negative results suggest that common polymorphisms in SLCO1B3 and ABCC3 genes do not influence the function of the encoded transporters to a large extent, and are not clinically important in the case of gallstone disease	SLCO1B3	gallstone disease
48	Negative results suggest that common polymorphisms in SLCO1B3 and ABCC3 genes do not influence the function of the encoded transporters to a large extent, and are not clinically important in the case of gallstone disease	ABCC3	gallstone disease
49	Negative results suggest that common polymorphisms in SLCO1B3 and ABCC3 genes do not influence the function of the encoded transporters to a large extent, and are not clinically important in the case of gallstone disease	ABCC3	gallstone disease
50	The presence of polymorphisms associated with the risk of developing gallstone disease in humans has been demonstrated in genes encoding plasma transport and catabolism of cholesterol proteins (APOE, APOB, APOA1), and in the cholesterol esters transporter protein gene (CEPT)	APOE	gallstone disease
51	The presence of polymorphisms associated with the risk of developing gallstone disease in humans has been demonstrated in genes encoding plasma transport and catabolism of cholesterol proteins (APOE, APOB, APOA1), and in the cholesterol esters transporter protein gene (CEPT)	APOE	gallstone disease
52	The presence of polymorphisms associated with the risk of developing gallstone disease in humans has been demonstrated in genes encoding plasma transport and catabolism of cholesterol proteins (APOE, APOB, APOA1), and in the cholesterol esters transporter protein gene (CEPT)	APOB	gallstone disease
53	The presence of polymorphisms associated with the risk of developing gallstone disease in humans has been demonstrated in genes encoding plasma transport and catabolism of cholesterol proteins (APOE, APOB, APOA1), and in the cholesterol esters transporter protein gene (CEPT)	APOB	gallstone disease
54	The presence of polymorphisms associated with the risk of developing gallstone disease in humans has been demonstrated in genes encoding plasma transport and catabolism of cholesterol proteins (APOE, APOB, APOA1), and in the cholesterol esters transporter protein gene (CEPT)	APOA1	gallstone disease
55	The presence of polymorphisms associated with the risk of developing gallstone disease in humans has been demonstrated in genes encoding plasma transport and catabolism of cholesterol proteins (APOE, APOB, APOA1), and in the cholesterol esters transporter protein gene (CEPT)	APOA1	gallstone disease
56	The APOE polymorphism is most frequently investigated in patients with gallstone disease.	APOE	gallstone disease
57	The APOE polymorphism is most frequently investigated in patients with gallstone disease.	APOE	gallstone disease
58	These studies demonstrated the association between cholesterol gallstone disease and the genes encoding liver regulatory enzymes (Hmgcr, Cypa1, Soat2), cholecystokinin receptor (Cckar), HDL receptor (Srb1), apolipoprotein (ApoE), basolateral organic cation transporter (Slc22a1), and tubular bile salt export pump (Abcb11).	Hmgcr	cholesterol gallstone disease
59	These studies demonstrated the association between cholesterol gallstone disease and the genes encoding liver regulatory enzymes (Hmgcr, Cypa1, Soat2), cholecystokinin receptor (Cckar), HDL receptor (Srb1), apolipoprotein (ApoE), basolateral organic cation transporter (Slc22a1), and tubular bile salt export pump (Abcb11).	Hmgcr	cholesterol gallstone disease
60	These studies demonstrated the association between cholesterol gallstone disease and the genes encoding liver regulatory enzymes (Hmgcr, Cypa1, Soat2), cholecystokinin receptor (Cckar), HDL receptor (Srb1), apolipoprotein (ApoE), basolateral organic cation transporter (Slc22a1), and tubular bile salt export pump (Abcb11).	Soat2	cholesterol gallstone disease
61	These studies demonstrated the association between cholesterol gallstone disease and the genes encoding liver regulatory enzymes (Hmgcr, Cypa1, Soat2), cholecystokinin receptor (Cckar), HDL receptor (Srb1), apolipoprotein (ApoE), basolateral organic cation transporter (Slc22a1), and tubular bile salt export pump (Abcb11).	Soat2	cholesterol gallstone disease
62	These studies demonstrated the association between cholesterol gallstone disease and the genes encoding liver regulatory enzymes (Hmgcr, Cypa1, Soat2), cholecystokinin receptor (Cckar), HDL receptor (Srb1), apolipoprotein (ApoE), basolateral organic cation transporter (Slc22a1), and tubular bile salt export pump (Abcb11).	Cckar	cholesterol gallstone disease
63	These studies demonstrated the association between cholesterol gallstone disease and the genes encoding liver regulatory enzymes (Hmgcr, Cypa1, Soat2), cholecystokinin receptor (Cckar), HDL receptor (Srb1), apolipoprotein (ApoE), basolateral organic cation transporter (Slc22a1), and tubular bile salt export pump (Abcb11).	Cckar	cholesterol gallstone disease
64	These studies demonstrated the association between cholesterol gallstone disease and the genes encoding liver regulatory enzymes (Hmgcr, Cypa1, Soat2), cholecystokinin receptor (Cckar), HDL receptor (Srb1), apolipoprotein (ApoE), basolateral organic cation transporter (Slc22a1), and tubular bile salt export pump (Abcb11).	Srb1	cholesterol gallstone disease
65	These studies demonstrated the association between cholesterol gallstone disease and the genes encoding liver regulatory enzymes (Hmgcr, Cypa1, Soat2), cholecystokinin receptor (Cckar), HDL receptor (Srb1), apolipoprotein (ApoE), basolateral organic cation transporter (Slc22a1), and tubular bile salt export pump (Abcb11).	Srb1	cholesterol gallstone disease
66	These studies demonstrated the association between cholesterol gallstone disease and the genes encoding liver regulatory enzymes (Hmgcr, Cypa1, Soat2), cholecystokinin receptor (Cckar), HDL receptor (Srb1), apolipoprotein (ApoE), basolateral organic cation transporter (Slc22a1), and tubular bile salt export pump (Abcb11).	apolipoprotein	cholesterol gallstone disease
67	These studies demonstrated the association between cholesterol gallstone disease and the genes encoding liver regulatory enzymes (Hmgcr, Cypa1, Soat2), cholecystokinin receptor (Cckar), HDL receptor (Srb1), apolipoprotein (ApoE), basolateral organic cation transporter (Slc22a1), and tubular bile salt export pump (Abcb11).	apolipoprotein	cholesterol gallstone disease
68	These studies demonstrated the association between cholesterol gallstone disease and the genes encoding liver regulatory enzymes (Hmgcr, Cypa1, Soat2), cholecystokinin receptor (Cckar), HDL receptor (Srb1), apolipoprotein (ApoE), basolateral organic cation transporter (Slc22a1), and tubular bile salt export pump (Abcb11).	ApoE	cholesterol gallstone disease
69	These studies demonstrated the association between cholesterol gallstone disease and the genes encoding liver regulatory enzymes (Hmgcr, Cypa1, Soat2), cholecystokinin receptor (Cckar), HDL receptor (Srb1), apolipoprotein (ApoE), basolateral organic cation transporter (Slc22a1), and tubular bile salt export pump (Abcb11).	ApoE	cholesterol gallstone disease
70	These studies demonstrated the association between cholesterol gallstone disease and the genes encoding liver regulatory enzymes (Hmgcr, Cypa1, Soat2), cholecystokinin receptor (Cckar), HDL receptor (Srb1), apolipoprotein (ApoE), basolateral organic cation transporter (Slc22a1), and tubular bile salt export pump (Abcb11).	Slc22a1	cholesterol gallstone disease
71	These studies demonstrated the association between cholesterol gallstone disease and the genes encoding liver regulatory enzymes (Hmgcr, Cypa1, Soat2), cholecystokinin receptor (Cckar), HDL receptor (Srb1), apolipoprotein (ApoE), basolateral organic cation transporter (Slc22a1), and tubular bile salt export pump (Abcb11).	Slc22a1	cholesterol gallstone disease
72	These studies demonstrated the association between cholesterol gallstone disease and the genes encoding liver regulatory enzymes (Hmgcr, Cypa1, Soat2), cholecystokinin receptor (Cckar), HDL receptor (Srb1), apolipoprotein (ApoE), basolateral organic cation transporter (Slc22a1), and tubular bile salt export pump (Abcb11).	Abcb11	cholesterol gallstone disease
73	These studies demonstrated the association between cholesterol gallstone disease and the genes encoding liver regulatory enzymes (Hmgcr, Cypa1, Soat2), cholecystokinin receptor (Cckar), HDL receptor (Srb1), apolipoprotein (ApoE), basolateral organic cation transporter (Slc22a1), and tubular bile salt export pump (Abcb11).	Abcb11	cholesterol gallstone disease
74	The ABCC3 gene rs4793665 polymorphism was significantly associated with methotrexate pharmacokinetics both in juvenile idiopathic arthritis and in pediatric osteosarcoma patients.	ABCC3	juvenile idiopathic arthritis
75	The ABCC3 gene rs4793665 polymorphism was significantly associated with methotrexate pharmacokinetics both in juvenile idiopathic arthritis and in pediatric osteosarcoma patients.	ABCC3	osteosarcoma
76	The ABCC3 gene rs4793665 polymorphism was significantly associated with methotrexate pharmacokinetics both in juvenile idiopathic arthritis and in pediatric osteosarcoma patients.	ABCC3	juvenile idiopathic arthritis
77	The ABCC3 gene rs4793665 polymorphism was significantly associated with methotrexate pharmacokinetics both in juvenile idiopathic arthritis and in pediatric osteosarcoma patients.	ABCC3	osteosarcoma
78	The SLCO1B3 gene rs4149117 and rs7311358 polymorphisms have been shown to affect the efficacy of statin treatment in patients with hypercholesterolemia	SLCO1B3	hypercholesterolemia
79	The SLCO1B3 gene rs4149117 and rs7311358 polymorphisms have been shown to affect the efficacy of statin treatment in patients with hypercholesterolemia	SLCO1B3	hypercholesterolemia
80	We cannot exclude minor effects of SLCO1B3 and ABCC3 genetic polymorphisms on gallstone disease risk and gallstone composition, which could be masked by the variability of environmental factors within investigated patient populations.	SLCO1B3	gallstone disease
81	We cannot exclude minor effects of SLCO1B3 and ABCC3 genetic polymorphisms on gallstone disease risk and gallstone composition, which could be masked by the variability of environmental factors within investigated patient populations.	SLCO1B3	gallstone
82	We cannot exclude minor effects of SLCO1B3 and ABCC3 genetic polymorphisms on gallstone disease risk and gallstone composition, which could be masked by the variability of environmental factors within investigated patient populations.	SLCO1B3	gallstone disease
83	We cannot exclude minor effects of SLCO1B3 and ABCC3 genetic polymorphisms on gallstone disease risk and gallstone composition, which could be masked by the variability of environmental factors within investigated patient populations.	SLCO1B3	gallstone
84	We cannot exclude minor effects of SLCO1B3 and ABCC3 genetic polymorphisms on gallstone disease risk and gallstone composition, which could be masked by the variability of environmental factors within investigated patient populations.	ABCC3	gallstone disease
85	We cannot exclude minor effects of SLCO1B3 and ABCC3 genetic polymorphisms on gallstone disease risk and gallstone composition, which could be masked by the variability of environmental factors within investigated patient populations.	ABCC3	gallstone
86	We cannot exclude minor effects of SLCO1B3 and ABCC3 genetic polymorphisms on gallstone disease risk and gallstone composition, which could be masked by the variability of environmental factors within investigated patient populations.	ABCC3	gallstone disease
87	We cannot exclude minor effects of SLCO1B3 and ABCC3 genetic polymorphisms on gallstone disease risk and gallstone composition, which could be masked by the variability of environmental factors within investigated patient populations.	ABCC3	gallstone
88	The results suggest that common polymorphisms in SLCO1B3 and ABCC3 genes are not a valuable marker of gallstone disease susceptibility and do not influence gallstone composition.	SLCO1B3	gallstone disease
89	The results suggest that common polymorphisms in SLCO1B3 and ABCC3 genes are not a valuable marker of gallstone disease susceptibility and do not influence gallstone composition.	SLCO1B3	gallstone
90	The results suggest that common polymorphisms in SLCO1B3 and ABCC3 genes are not a valuable marker of gallstone disease susceptibility and do not influence gallstone composition.	SLCO1B3	gallstone disease
91	The results suggest that common polymorphisms in SLCO1B3 and ABCC3 genes are not a valuable marker of gallstone disease susceptibility and do not influence gallstone composition.	SLCO1B3	gallstone
92	The results suggest that common polymorphisms in SLCO1B3 and ABCC3 genes are not a valuable marker of gallstone disease susceptibility and do not influence gallstone composition.	ABCC3	gallstone disease
93	The results suggest that common polymorphisms in SLCO1B3 and ABCC3 genes are not a valuable marker of gallstone disease susceptibility and do not influence gallstone composition.	ABCC3	gallstone
94	The results suggest that common polymorphisms in SLCO1B3 and ABCC3 genes are not a valuable marker of gallstone disease susceptibility and do not influence gallstone composition.	ABCC3	gallstone disease
95	The results suggest that common polymorphisms in SLCO1B3 and ABCC3 genes are not a valuable marker of gallstone disease susceptibility and do not influence gallstone composition.	ABCC3	gallstone
96	ABCB4 gene mutation:Associated cholelithiasis in adults	ABCB4	cholelithiasis
97	ABCB4 gene mutation:Associated cholelithiasis in adults	ABCB4	cholelithiasis
98	A genome-wide association scan identifies the hepatic cholesterol transporter ABCG8 as a susceptibility factor for human gallstone disease	ABCG8	human gallstone disease
99	A genome-wide association scan identifies the hepatic cholesterol transporter ABCG8 as a susceptibility factor for human gallstone disease	ABCG8	human gallstone disease
100	Up-regulation of basolateral multidrug resistance protein 3 (Mrp3) in cholestatic rat liver	multidrug resistance protein 3	cholestatic
101	Up-regulation of basolateral multidrug resistance protein 3 (Mrp3) in cholestatic rat liver	multidrug resistance protein 3	cholestatic
102	Up-regulation of basolateral multidrug resistance protein 3 (Mrp3) in cholestatic rat liver	Mrp3	cholestatic
103	Up-regulation of basolateral multidrug resistance protein 3 (Mrp3) in cholestatic rat liver	Mrp3	cholestatic
104	Multidrug resistance-associated protein 4 is up-regulated in liver but down-regulated in kidney in obstructive cholestasis in the rat	Multidrug resistance-associated protein 4	obstructive cholestasis
105	Multidrug resistance-associated protein 4 is up-regulated in liver but down-regulated in kidney in obstructive cholestasis in the rat	Multidrug resistance-associated protein 4	obstructive cholestasis
106	Influence of SLCO1B3 Gene Polymorphism on the Pharmacokinetics of Digoxin in Terminal Renal Failure	SLCO1B3	Terminal Renal Failure
107	Influence of SLCO1B3 Gene Polymorphism on the Pharmacokinetics of Digoxin in Terminal Renal Failure	SLCO1B3	Terminal Renal Failure
108	A Variant of the SLC10A2 Gene Encoding the Apical Sodium-Dependent Bile Acid Transporter Is a Risk Factor for Gallstone Disease	SLC10A2	Gallstone Disease
109	A Variant of the SLC10A2 Gene Encoding the Apical Sodium-Dependent Bile Acid Transporter Is a Risk Factor for Gallstone Disease	SLC10A2	Gallstone Disease
110	Increased gallstone risk in humans conferred by common variant of hepatic ATP-binding cassette transporter for cholesterol	ATP-binding cassette transporter	gallstone
111	Increased gallstone risk in humans conferred by common variant of hepatic ATP-binding cassette transporter for cholesterol	ATP-binding cassette transporter	gallstone
112	Organic anion transporter protein (OATP1B1) encoded by SLCO1B1 gene polymorphism (388A>G) & susceptibility in gallstone disease	OATP1B1	gallstone disease
113	Organic anion transporter protein (OATP1B1) encoded by SLCO1B1 gene polymorphism (388A>G) & susceptibility in gallstone disease	OATP1B1	gallstone disease
114	Organic anion transporter protein (OATP1B1) encoded by SLCO1B1 gene polymorphism (388A>G) & susceptibility in gallstone disease	SLCO1B1	gallstone disease
115	Organic anion transporter protein (OATP1B1) encoded by SLCO1B1 gene polymorphism (388A>G) & susceptibility in gallstone disease	SLCO1B1	gallstone disease
116	Apolipoprotein B (APOB) Gene Polymorphism in Patients with Gallbladder Disease	Apolipoprotein B	Gallbladder Disease
117	Apolipoprotein B (APOB) Gene Polymorphism in Patients with Gallbladder Disease	Apolipoprotein B	Gallbladder Disease
118	Apolipoprotein B (APOB) Gene Polymorphism in Patients with Gallbladder Disease	APOB	Gallbladder Disease
119	Apolipoprotein B (APOB) Gene Polymorphism in Patients with Gallbladder Disease	APOB	Gallbladder Disease
120	Cholesterol 7alpha-hydrolase (CYP7A1) c.-278A>C promoter polymorphism in gallstone disease patients	CYP7A1	gallstone disease
121	Cholesterol 7alpha-hydrolase (CYP7A1) c.-278A>C promoter polymorphism in gallstone disease patients	CYP7A1	gallstone disease
122	Lith1, a major gene affecting cholesterol gallstone formation among inbred strains of mice	Lith1	gallstone
123	Lith1, a major gene affecting cholesterol gallstone formation among inbred strains of mice	Lith1	gallstone
124	ABCB1 and ABCC3 gene polymorphisms are associated with first-year response to methotrexate in juvenile idiopathic arthritis	ABCB1	juvenile idiopathic arthritis
125	ABCB1 and ABCC3 gene polymorphisms are associated with first-year response to methotrexate in juvenile idiopathic arthritis	ABCB1	juvenile idiopathic arthritis
126	ABCB1 and ABCC3 gene polymorphisms are associated with first-year response to methotrexate in juvenile idiopathic arthritis	ABCC3	juvenile idiopathic arthritis
127	ABCB1 and ABCC3 gene polymorphisms are associated with first-year response to methotrexate in juvenile idiopathic arthritis	ABCC3	juvenile idiopathic arthritis
128	ABCC3 and GSTM5 gene polymorphisms affect overall survival in Polish acute myeloid leukaemia patients	ABCC3	acute myeloid leukaemia
129	ABCC3 and GSTM5 gene polymorphisms affect overall survival in Polish acute myeloid leukaemia patients	ABCC3	acute myeloid leukaemia
130	ABCC3 and GSTM5 gene polymorphisms affect overall survival in Polish acute myeloid leukaemia patients	GSTM5	acute myeloid leukaemia
131	ABCC3 and GSTM5 gene polymorphisms affect overall survival in Polish acute myeloid leukaemia patients	GSTM5	acute myeloid leukaemia
132	Late response to rosuvastatin and statin-related myalgia due to SLCO1B1, SLCO1B3, ABCB11, and CYP3A5 variants in a patient with Familial Hypercholesterolemia: A case report	SLCO1B1	myalgia
133	Late response to rosuvastatin and statin-related myalgia due to SLCO1B1, SLCO1B3, ABCB11, and CYP3A5 variants in a patient with Familial Hypercholesterolemia: A case report	SLCO1B1	myalgia
134	Late response to rosuvastatin and statin-related myalgia due to SLCO1B1, SLCO1B3, ABCB11, and CYP3A5 variants in a patient with Familial Hypercholesterolemia: A case report	SLCO1B3	myalgia
135	Late response to rosuvastatin and statin-related myalgia due to SLCO1B1, SLCO1B3, ABCB11, and CYP3A5 variants in a patient with Familial Hypercholesterolemia: A case report	SLCO1B3	myalgia
136	Late response to rosuvastatin and statin-related myalgia due to SLCO1B1, SLCO1B3, ABCB11, and CYP3A5 variants in a patient with Familial Hypercholesterolemia: A case report	ABCB11	myalgia
137	Late response to rosuvastatin and statin-related myalgia due to SLCO1B1, SLCO1B3, ABCB11, and CYP3A5 variants in a patient with Familial Hypercholesterolemia: A case report	ABCB11	myalgia
138	Late response to rosuvastatin and statin-related myalgia due to SLCO1B1, SLCO1B3, ABCB11, and CYP3A5 variants in a patient with Familial Hypercholesterolemia: A case report	CYP3A5	myalgia
139	Late response to rosuvastatin and statin-related myalgia due to SLCO1B1, SLCO1B3, ABCB11, and CYP3A5 variants in a patient with Familial Hypercholesterolemia: A case report	CYP3A5	myalgia
140	Late response to rosuvastatin and statin-related myalgia due to SLCO1B1, SLCO1B3, ABCB11, and CYP3A5 variants in a patient with Familial Hypercholesterolemia: A case report	SLCO1B1	Familial Hypercholesterolemia
141	Late response to rosuvastatin and statin-related myalgia due to SLCO1B1, SLCO1B3, ABCB11, and CYP3A5 variants in a patient with Familial Hypercholesterolemia: A case report	SLCO1B1	Familial Hypercholesterolemia
142	Late response to rosuvastatin and statin-related myalgia due to SLCO1B1, SLCO1B3, ABCB11, and CYP3A5 variants in a patient with Familial Hypercholesterolemia: A case report	SLCO1B3	Familial Hypercholesterolemia
143	Late response to rosuvastatin and statin-related myalgia due to SLCO1B1, SLCO1B3, ABCB11, and CYP3A5 variants in a patient with Familial Hypercholesterolemia: A case report	SLCO1B3	Familial Hypercholesterolemia
144	Late response to rosuvastatin and statin-related myalgia due to SLCO1B1, SLCO1B3, ABCB11, and CYP3A5 variants in a patient with Familial Hypercholesterolemia: A case report	ABCB11	Familial Hypercholesterolemia
145	Late response to rosuvastatin and statin-related myalgia due to SLCO1B1, SLCO1B3, ABCB11, and CYP3A5 variants in a patient with Familial Hypercholesterolemia: A case report	ABCB11	Familial Hypercholesterolemia
146	Late response to rosuvastatin and statin-related myalgia due to SLCO1B1, SLCO1B3, ABCB11, and CYP3A5 variants in a patient with Familial Hypercholesterolemia: A case report	CYP3A5	Familial Hypercholesterolemia
147	Late response to rosuvastatin and statin-related myalgia due to SLCO1B1, SLCO1B3, ABCB11, and CYP3A5 variants in a patient with Familial Hypercholesterolemia: A case report	CYP3A5	Familial Hypercholesterolemia
